Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform with Taiho Ventures, Sofinnova Partners, and Invivo Partners.
PRIVATEMay 06, 2026•4 months ago
Amount Raised
€11.1 Million
Round Type
Seed
ParisBiotechnologyTherapeuticsBiopharma
Investors
Invivo PartnersSofinnova PartnersTaiho Ventures
Description
Signadori Bio SAS has successfully completed its seed extension financing round, raising a total of €11.1 million. This funding will support the advancement of its lead immunotherapy program SiB-2101 and the development of its proprietary platform. The investment included participation from Taiho Ventures and existing investors. This milestone will help drive the company closer to clinical trials and enhance its operational capabilities.
Company Information
Company
Signadori Bio
Location
Paris, Ile De France, France
About
Signadori Bio is a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours. Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, Signadori aims to harness the immune potential of gene-modified monocytes. It is based in Paris and backed by Sofinnova Partners.
Don't miss Signadori Bio's next move
Get an email the moment Signadori Bio raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contactsThomas C., Chief Development Officer (part-time)
Predictive Intelligence
Strategic
ML-powered predictions for Signadori Bio's next move
ParisBiotechnologyTherapeuticsBiopharma